Merck announces $0.81 dividend and $10 billion buyback
Co., Inc. (NYSE:MRK), a global healthcare leader, declared on Monday a quarterly dividend and a substantial stock repurchase ...
pharmaphorum22h
Merck turns to cardiovascular pipeline for its post-Keytruda future
During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...